## e-Protocol

# PROTOCOL ARS Form USDA

Personnel Information
Species
Agent Information
Rationale4
Procedures
Literature Search
Sequence and Timing
Husbandry16
Euthanasia
Guidelines
Certifications



#### Protocol # ARS-2019-827 December 18, 2019

For Official Use Only

Protocol Title:	Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.
Protocol Type:	ARS Form
Approval Period:	11/25/2019-11/24/2022
Important Note:	This Print View may not reflect all comments and contingencies for approval. Please check the comments section of the online protocol.

## \* \* \* Personnel Information \* \* \*

## PRINCIPAL INVESTIGATOR

The Principal Investigator can view, edit, and submit protocol.

## **Principal Investigator**

Name*	Department	
Greenlee, Justin	Virus and Prion Research Unit	
Email*	Phone	
Justin.Greenlee@ARS.USDA.GOV	515-337-7191	

## CO-PRINCIPAL INVESTIGATOR(S)

## Co-Principal Investigator(s)

Name	Department	Email

## OTHER PERSONNEL

Name	Department	Email

List at least two contacts. If more than two are listed, the first two entered will appear on door card.

Emergency Contact			After Hours Numb	er
Name		Extension		

\* \* \* Species \* \* \*



For Official Use Only

Protocol Title: Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

#### Species to be Used

Species Common Name		Maximum number of animals requested for this species for this housing location (total 1 year)
Deer	As Assigned by ARU	120

#### Species to be Used

1.	Species Common Name*	Deer			
2.	Scientific Name	Cervidae			
3.	Strain/Breed	Whitetail			
4.	Animal Sex*	Either			
5.	Age Range	0	-	12	Year(s)
6.	Weight Range		-		Kg(s)
7.	Proposed Housing Facility*	As Assigne	d by	ARU	
		4 B/C			

8. USDA Pain Category (Choose all that will apply. Enter the total number of the species to be used in each Pain Category. If animals will be used in more than one category, enter the number in the higher category.\*

	Pain Category B	
	Pain Category C	
	Pain Category D	
Х	Pain Category E	120
Maxim	num number of animals requested for this	120

- 9. Maximum number of animals requested for this <sup>120</sup> species for this housing location (total 1 year)\*
- 10. State whether enrichment should be provided <sup>Yes</sup> (YES or NO). If no, give a scientific justification why not.

11. Have any of the animals undergone procedures prior to being used on N this protocol?

Please specify which animals underwent procedures, what procedures were performed, and where those procedures were performed.

-------

\* \* \* Agent Information \* \* \*

Agent Information - Collaboration and Safety Concerns

1. Biological Material / Human or Animal Product(s) / Infectious Agent(s)\*

Are you using biological material, human or animal products, or infectious agents?

Y



For Official Use Only

Protocol Title:

Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

## Biological Material / Human or Animal Product(s) / and /or Infectious Agent

Specify Material or Agent	Spread by
<b>a</b> 1	exposure to infected deer or contaminated environments

## Biological Material / Human or Animal Product(s) / and /or Infectious Agent

1.a.	Specify Material or Agent(s)*	Chronic wasting disease prion
1.b.	Strain/Type of Agent* prion	
1.c.	Spread by*	exposure to infected deer or contaminated environments
1.d.	Route of Administration*	Oronasally
1.e.	Is this agent a known pathogen to	Animal
1.f.	ls this agent(s) a select agent?	Ν
1.g.	Does this protocol use recombinants/Genetic Engineering Organisms?	Ν
	If yes, provide IBC number	
	Expiration date	

#### 2. Other Agents or Substances\*

Ν

In this section please specify any additional substances such as hormones, novel antibiotics, cytokines, inhibitors, non-toxic irritants, etc., that are not covered above in section.

## 3. Entry Procedures

#### Entry Procedures(for the agent)

x	Complete Clothes Change		Lab Coat
х	Boots/Shoe Covers	Х	Face Shield
	Shower In		Safety Glasses
х	Gloves		Surgical or Dust Mask
	Hair Net		Tyvek
х	Other(fill out textbox below)		Respirator(state type in textbox below)
	When mist is produced (during pen washing or inoculation), a faceshield or surgical/procedural mask should be worn to prevent splashing into the nose or mouth. N95 respirators will be available to all personnel. Change clothes in.		

## 4. Exit Procedures

## Exit Procedures(for the agent)



For Official Use Only

Protocol Title:

Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

X	Wash Hands & Forearms	Х	Shower Out
	Other(fill out textbox below)		Wash/Disinfect Footwear

#### \_\_\_\_\_

#### \* \* \* Rationale \* \* \*

USDA Protocol ID (for office use only)

#### Official Project Title

Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

#### **Study Objectives**

#### 1. Objectives and Significance

#### a. Provide a brief synopsis of the research project covered by this protocol and its overall objective(s).\*

Most white-tailed deer appear to be highly susceptible to the chronic wasting disease (CWD) agent. Deer with specific amino acid combinations (polymorphisms) in their prion protein have been shown to be unrepresented in the CWD positive cases from premises with large numbers of positive deer. This purpose of this study is to test for potential resistant genotypes of deer through direct inoculation and exposure to infected deer of known susceptible genotypes and characterize shedding of the abnormal prion protein in deer that become infected.

#### b. Why is the study important to human or animal health, the advancement of knowledge, or the good of society?\*

Since originating on a single premises, CWD has spread worldwide. Identifying resistant genotypes of deer would provide a management tool for reducing cases of CWD on farms and in the wild.

#### 2. Rationale for Use of Animals

a. How will the use of animals help you accomplish the project goal(s)? Explain why those goals could not be achieved using in vitro or computer models.\*

Using deer for this experiment will allow us to better understand CWD transmission and the potential to use selective breeding as a control measure. Using deer is essential to reaching the goals of this project. In vitro and computer models do not have the complexity required to evaluating prion agent resistance in the natural host.

#### b. Why are the species you have selected the most appropriate for these studies?\*

White-tailed deer (WTD) are the most appropriate species for these studies because more cases of CWD have been identified in WTD than any other cervid species, WTD are the most widely distributed species of deer in North America, and amino acid changes in the WTD prion protein are well-described.

c. Indicate how group sizes (number of animals per project) were determined. Justification for these numbers using an appropriate statistical assessment such as a Power Analysis is expected. If a Power Analysis is not appropriate (e.g., pilot studies, tissue protocols, etc.) provide a detailed description of how the requested number of animals was determined. Be sure to include descriptions of the groups (e.g. Control, treatment, etc.) and the numbers of animals included in each group. \*

There are 3 polymorphic sites in the prion protein of white-tailed deer that we wish to assess in this protocol: codons 95, 96, and 226. Studies covered in this protocol will require assessment of up to 10 genotypes of deer. Numbers requested for this experiment are for two purposes: 1) assess susceptibility after direct inoculation (60; 6 deer of up to 10 different genotypes) and 2) assess susceptibility of these genotypes after cohousing with infected deer to model natural exposure (60, which requires direct inoculation of up to 20 deer of susceptible genotypes and exposure by co-housing to up to 40 deer of potentially resistant genotypes). We plan to use 5-6 deer per group similar to previously published studies (Greenlee, J. J., Smith, J. D. and Kunkle, R.

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019
	pc	camination of deer with prion protein a tential resistance to exposure to the jent.	
	A. White-tailed deer are susceptible to	the agent of sheep scrapie by intracerebral in	oculation. Vet Res. 42 (1): 107. 2011).
	Testing the potential of the CWD agen of 10 genotypes). All exposure will be	t to transmit to deer after oronasal exposure w	vill require up to 60 deer (up to 6 deer per each
	Testing the potential of the CWD agen deer per group, each group will contai	t to transmit to deer after cohousing with infec n 2 deer infected deer and 4 of the each of the y the intranasal/oral route and cohoused with o	e 10 genotypes being tested). The infected
	All groups will be similarly assessed for		5
		* * * Procedures * * *	
		Biopsy	
1.	Procedure Type:	Biopsy	
2.	Brief Description:	rectal mucosal biopsy with use of to	opical lidocaine lubricant
3.	Species:	Deer (As Assigned by ARU)	
4.	USDA Pain/Distress Category:	D	
5.	Maximum number of animals to be used in this procedure:	120	
6.	missing details will prevent the p	ress all of the questions for each tab tropped to the last transmitted to the	
	*	* * Procedure Description * * *	
Proce	edure Description		
1.	Detailed Procedure Description		
	and other peripheral structures w the Peyer's patches of the small prion protein by immunohistoche simple biopsy procedure is used	vith similar populations of lymphoid ce	e appropriate for testing for abnormal ining at the rectal-anal junction. A iefly, a speculum is inserted into the

	USDA	PROTOCOL ARS Form USDA	Protocol # ARS-2019- 827 December 18, 2019
		For Official Use Only	
	Protocol Title:	Examination of deer with prion protein a potential resistance to exposure to the c agent.	mino acid polymorphisms for hronic wasting disease (CWD)
	sized piece of mucosa, which staining. Previous experien Complications are rare, and The biggest risk with perform which can lead to injured de valuable data when assessi we ensure that there is ade possible. Multiple biopsies (	inside the rectal-anal junction; scissors are ch is processed for microscopic examination ices with elk and sheep suggest that this pr I there is minimal evidence of biopsy detect ming this procedure in white-tailed deer is a eer if physical restraint is not adequate. Thi ng transmission of CWD to sentinel deer. I quate staff on hand to manipulate the deer up to every two months) may be obtained of ns around the circumference of the rectum. d in the technique.	n and immunohistochemical ocedure will be well tolerated. able two weeks post-procedure. issociated with handling the deer, s procedure could yield very f we choose to use this technique, as quickly, quietly, and safely as over the course of the experiment by
2.	untreated animal which may Immediately after the proce	clinical effects or changes from the normal occur as a result of this procedure. dure, there may be a small amount of bleed	
3.		nitoring, observation schedules, and treatm	
	Deer will be observed imme	diately after the procedure and daily during	normal observation periods.
4.	What criteria will be used to euthanized?	determine if animals exhibiting clinical or be	ehavioral changes should be
	No signs requiring euthanas	sia are expected as a consequence of this p	procedure.
		* * * Anesthetic Regimen * * *	
Anes	sthetic Regimen		
	1. Parameters used to m	nonitor and ensure appropriate anesthetic d	epth.
	Anesthetic Agents		


	Dosage (in mg/kg if possible) AND Volume of Administration (when applicable)	Route
Lidocaine	2-3 ml of 0.2% lidocaine in lubricant	Topical

\_\_\_\_\_

\_\_\_\_\_

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019
	Protocol Title:	Examination of deer with prion protein an potential resistance to exposure to the clagent.	mino acid polymorphisms for hronic wasting disease (CWD)
		* * * Perioperative Care * * *	
Perio	operative Care		
	Describe what parameters v	vill be monitored during surgery to ensure p	roper analgesia.
	Post-operative Monitoring Note: A minimum of 24 hours and a minimum of 48 hours of All animals must be monitore administration ceased.	s of post-operative analgesia must be provic of post-operative analgesia must be provide d for 96 hours (4 DAYS) following surgery r	led for minor surgical procedures d for major operative procedures. egardless of when analgesic
	1. Recovery Location - Facil	ity or Building Name	
	2. Room Number		
	3. Personnel Responsible fo	r Monitoring Recovery	
	4. What parameters are mor	nitored to assess recovery?	
	5. Recovery - What is the du monitoring?	ration and frequency of the	
	6. Post-recovery - What is th the monitoring ?	e duration and frequency of	
		* * * Pharmaceuticals * * *	
Phar	maceuticals		
		Animal Identification	
1.	Procedure Type:	Animal Identification	

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019
	рс	amination of deer with prion protein tential resistance to exposure to the ent.	amino acid polymorphisms for chronic wasting disease (CWD)
2. 3. 4. 5.	Brief Description: Species: USDA Pain/Distress Category: Maximum number of animals to be used in this procedure:	ear tags will be applied, this may re Deer (As Assigned by ARU) C 120	equire making an ear punch
6.	Please click 'save' and then addr missing details will prevent the p	rotocol from being submitted to the IA	that will appear below. Incomplete or ACUC for review.
Proc	* edure Description	* * Procedure Description * * *	
1.	An ear punch tool will be used to	lentification as each room may conta remove a piece of ear skin/cartilage ble with the punch greatly reduces co	in up to 6 deer that look very similar. and ear tag pliers will be used to omplications due to infection.
2.	Please list and describe any clinic untreated animal which may occu No clinical effects are anticipated	-	al health and behavior of an
3.		<b>ng, observation schedules, and treat</b> ely after the procedure, upon returnin he experiment.	-
4.	euthanized?	mine if animals exhibiting clinical or l	-
		* * * Pharmaceuticals * * *	
Phar	maceuticals		 Page (



USDA	PROTOCOL ARS Form USDA	Protocol # ARS-2019- 827 December 18, 2019
	For Official Use Only	
р	xamination of deer with prion protein otential resistance to exposure to the gent.	
reveal unequivocal signs of prio	n disease.	
	* * * Pharmaceuticals * * *	
Pharmaceuticals		
	Blood Collection (non-terminal)	
1. Procedure Type:	Blood Collection (non-terminal)	
2. Brief Description:	IV blood collection from jugular veil	n
3. Species:	Deer (As Assigned by ARU)	
4. USDA Pain/Distress Category:	C	
5. Maximum number of animals to be used in this procedure:	120	
<ol> <li>Please click 'save' and then add missing details will prevent the prevent the</li></ol>	Iress all of the questions for each tab protocol from being submitted to the I	that will appear below. Incomplete or ACUC for review.
*	* * Procedure Description * * *	
Procedure Description		
. Detailed Procedure Description		
confirming deer genotypes. Bloc SOP ARU 0300. The expected	ed for use in developing new assays od collection will be performed from th schedule for collections is up to every r volumes (not to exceed 200 ml) may	
<ol> <li>Please list and describe any clin untreated animal which may occ</li> </ol>	ical effects or changes from the norm ur as a result of this procedure.	al health and behavior of an
No clinical effects are expected		

	USDA	PROTOCOL ARS Form USDA	Protocol # ARS-2019- 827 December 18, 2019
		For Official Use Only	
	ро	amination of deer with prion protein tential resistance to exposure to the ent.	
3.	Describe post procedure monitori	ng, observation schedules, and trea	tment that will be performed.
	Monitoring will occur during and a daily observation periods through	after the procedure, upon returning t nout the experiment.	he deer to their rooms, and during
4.	euthanized?	mine if animals exhibiting clinical or	
	No changes warranting euthanas	ia are expected from this procedure	
		* * * Pharmaceuticals * * *	
Phar	maceuticals		
		Biopsy	
1.	Procedure Type:	Biopsy	
2.	Brief Description:	skin biopsy	
<b>3.</b> 4.	Species: USDA Pain/Distress Category:	Deer (As Assigned by ARU) C	
5.	Maximum number of animals to be used in this procedure:	120	
6.	Please click 'save' and then addr missing details will prevent the p	ess all of the questions for each tab rotocol from being submitted to the l	that will appear below. Incomplete or ACUC for review.
	**	* * Procedure Description * * *	
Proce	edure Description		
1.	Detailed Procedure Description		
	A skin biopsy may be taken to as	sess for CWD prions. While deer an vill be used to to take a small (3x5x5	e physically restrained for periodic mm) wedge shaped piece of skin

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019	
	Protocol Title:	Examination of deer with prion protein a potential resistance to exposure to the a agent.	amino acid polymorphisms for chronic wasting disease (CWD)	
2.	untreated animal which may a Immediately after the proced	clinical effects or changes from the norma occur as a result of this procedure. ure, there may be a small amount of blee clinical effects or consequences are expect	ding from the margins of the excised	
3.		itoring, observation schedules, and treated liately after the procedure and daily during	-	
4.	euthanized?	etermine if animals exhibiting clinical or b a are expected as a consequence of this * * * Anesthetic Regimen * * *	-	
Anes	othetic Regimen 1. Parameters used to mo	onitor and ensure appropriate anesthetic o	depth.	

	USDA	PROTOCOL ARS Form USDA	Protocol # ARS-2019- 827 December 18, 2019
		For Official Use Only	
	Protocol Title:	Examination of deer with prion protein an potential resistance to exposure to the ch agent.	nino acid polymorphisms for Ironic wasting disease (CWD)
		* * * Perioperative Care * * *	
Perio	operative Care		
	Describe what parameters w	ill be monitored during surgery to ensure pr	oper analgesia.
	Post-operative Monitoring		
	and a minimum of 48 hours of	of post-operative analgesia must be provide f post-operative analgesia must be provided d for 96 hours (4 DAYS) following surgery re	for major operative procedures.
	1. Recovery Location - Facili	ty or Building Name	
	2. Room Number		
	3. Personnel Responsible for	Monitoring Recovery	
	4. What parameters are mon	itored to assess recovery?	
	5. Recovery - What is the dur monitoring?	ration and frequency of the	
	6. Post-recovery - What is the the monitoring ?	e duration and frequency of	
		* * * Pharmaceuticals * * *	
Phar	maceuticals		
		Sample Collection	
1.	Procedure Type:	Sample Collection	

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019
	po	xamination of deer with prion protein a otential resistance to exposure to the gent.	amino acid polymorphisms for chronic wasting disease (CWD)
2.	Brief Description:	collection of saliva, feces, urine	
2. 3.	Species:	Deer (As Assigned by ARU)	
<b>4</b> .	USDA Pain/Distress Category:	C	
5.	Maximum number of animals to be used in this procedure:	120	
6.	Please click 'save' and then add missing details will prevent the p	ress all of the questions for each tab t rotocol from being submitted to the IA	that will appear below. Incomplete or ACUC for review.
	*	* * Procedure Description * * *	
Proc	edure Description		
1.	intervals of up to every two mont collected with a transfer pipette of saliva on an absorbent pad. Fee	ths while deer are physically restraine or by using a collection system such a	as the "Super SAL" kit that collects n or digitally prior to performing rectal
2.	untreated animal which may occu	•	al health and behavior of an
	No long term clinical effects or c	onsequences are expected.	
3.	Describe post procedure monitor	ing, observation schedules, and treat	ment that will be performed
0.		ely after the procedure and daily durin	
4.	What criteria will be used to dete euthanized?	rmine if animals exhibiting clinical or t	behavioral changes should be
		re expected as a consequence of this	procedure.
		* * * Pharmaceuticals * * *	
Phar	maceuticals		
			Page 14 of 19

<u>USDA</u>		PROTO ARS F USE	Form	Protocol # ARS-2019- 827 December 18, 2019
		For Official	Use Only	
	Protocol Title:	Examination of deer wi potential resistance to agent.	ith prion protein exposure to the	amino acid polymorphisms for chronic wasting disease (CWD)
		* * * Literature Se	arch * * *	
Litera	uture Search for Altern	atives to the Use of Anima	ls AND Alternati	ves to Painful or Distressful
Proce	edures.			
Sear	ch Data			
Sear	ch Range From		Search Range	То
1965	5		2019	
Sear	ch Data			
1.a.	Search Range From	ז*	1965	(YYYY)
1.b.	Search Range To*		2019	(YYYY)
1.c.	Search Date*		09/24/201	9 (MM/DD/YYYY)
	Note: Because this to use the word "alte described in this pro	ernative" as a search term a	to painful or dist along with words	tressful procedures, you are advised s that describe the painful procedures
1.d.	Keywords* chronic wasting disease, deer, transmission, pathogenesis, alternative, animal use			
1.e.	Databases Searche	d*		
	Agricola Database		X Pubmed	
Х	Google Scholar Other		Digitop	
be co alterr	d on your literature se mpatible with your ex native(s).	perimental design? If "yes"	s, replacements, , please explain	, reductions or alternatives that would why you are not using the
INU all				
latt	estigator's experiments.* natives for Category E ntegory E procedures, expla	Procedures		xperiments, whether my own or another ments cannot be used to alleviate
For Ca	stress			te intercurrent diagona Animala era reguestas
For Ca pain/di Drugs in cate	will be used to alleviate pa	in and distress that occurs during that they will exhibit clinical signs atments for prion disease.	procedures or due t as a result of being	inoculated with a prion disease agent.

1.

2.

3.

4.

5.

	USDA	PROTOCOL ARS Form USDA For Official Use Only	Protocol # ARS-2019- 827 December 18, 2019		
	Protocol Title:	Examination of deer with prion protein potential resistance to exposure to the agent.			
6.	Unforeseen Events X If unforeseen events such as injury as possible for appropriate treatme	or illness unrelated to experimental procedures on the animal will be euthanized. *	occur, a veterinarian will be contacted as soon		
		* * * Sequence and Timing * * *			
Seq	uence and Timing				
1.	group of experiments, drugs and subs	ning of all the manipulations for each group of an tances administered in each group, the time betw	ween procedures, and experimental endpoints.		
	Use enough detail to allow reviewers to understand what each animal may undergo. Please separate paragraphs with a blank line. Deer will be assigned to one of two groups: 1) direct inoculation of potentially resistant genotypes (60 deer) or 2) exposure of deer of potentially resistant genotypes (4/room) to CWD by co-housing with inoculated animals of the most common/susceptible genotype (2/room) (60 total, 20 inoculated, 40 exposed by co-housing). Animals will be inoculated (n=80) and housed in groups or cohoused with non-inoculated deer (n=40). All deer will be observed daily for clinical signs. Prior to inoculation and periodically (up to every two months) deer (n=120) may be physically restrained for collection of blood, urine, and feces; rectal mucosal biopsy (with use of 0.2% lidocaine in the lubricant); and skin biopsy. Deer will be euthanized and necropsied when definitive signs of CWD are present such as altered gait, tremor, or behavioral change, which may occur in conjunction with weight loss. Clinical signs are expected 18-60 months post-inoculation. If inoculated animals fail to develop clinical signs 60-84 months post-inoculation, the experiment will be ended and tissues will be collected for analysis.				
2.	procedures flow chart with this protoco animals will undergo starting with their	edures, note the time period between procedure	nological order all the procedures that the hanasia. Indicate the timeline for the events (i.e.,		
		* * * Husbandry * * *			
1.	Special Husbandry or Care				
	special diet or supplements, s	quirements for the care of animal subject pecial water, altered light cycles, etc.). any feed containing animal ingredients	Indicate N/A, if not applicable.		
N	on-Standard Experimental Requ	uirements			
2.	Food or Fluid Restriction Note: This does not include pr	X None e-surgical fasting.			
	Food or Fluid restriction				



For Official Use Only

Protocol Title: Ex

Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

Species	Food Restriction	Duration and Frequency of Restriction		Reason for Restriction
Deer (As Assigned by ARU)				

- Describe the health monitoring procedures (e.g., body weight, blood urea nitrogen, urine/fecal output, food/fluid consumed), frequency of checks, and the method of ensuring adequate nutrition and hydration during the regulated period.
- Restraint of Conscious Animals X None
   Note: Include only prolonged restraint; brief restraint or restraint of anesthetized animals need not be described.

Restraint of Conscious Animals

Species		Duration and frequency of restraint
Deer (As Assigned by ARU)		

- 5. Please justify the need for the restraint prolonged and describe the monitoring procedures and criteria for removing animals that do not adapt or acclimate to the restraint.
- 6. Non-standard housing requirements Х None Cage/Pen Size Cage Sanitation Wire-bottom Animals outside Exemption from Species Interval rodent cages or dedicated social housing or animal housing for greater than 12 hours grids enrichment Deer (As Assigned by ARU)

7. Provide a description of the non-standard housing and justify why it is needed for your experimental design.

\* \* \* Euthanasia \* \* \*



For Official Use Only

Protocol Title: Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

#### Euthanasia

	Dosage (in mg/kg if possible) or inhalation or immersion agent, the concentration	Species	Route of Administration
Barbiturates (Sodium Pentobarbital)	As per label instructions or as directed by an ARU veterinarian		Intravenous

## Euthanasia

Species Method of Euthanasia Primary Deer (As Assigned by ARU) Barbiturates (Sodium Pentobarbital)

* * * Guidelines * * *				
Mandatory (view and check Yes)				
Respirator Fit Test & Training	AGREE			
Non-Mandatory (view those relevant and check Yes)				
Unforeseen Events	AGREE			

\* \* \* Certifications \* \* \*

## STATEMENT CONCERNING THE CARE AND USE OF LABORATORY ANIMALS

The NADC has on file with NIH's Office of Laboratory Animal Welfare (OLAW) a written Assurance of Compliance which commits this institution to following the standards established by Public Health Service (PHS) Policy. As part of the Assurance, NADC has established an institutional animal care and use committee (IACUC) to review, require changes to, and/or grant approval to research protocols or teaching projects involving the use of vertebrate animals. The IACUC is also charged with ascertaining if research proposals are consistent with the "US Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training"; the Guide for the Care and Use of Laboratory Animals, National Research Council; the Animal Welfare Act/Regulations, and the Guide for the Care and Use of Agricultural Animal in Research and Teaching, Federation of Animal Science Societies. These regulatory documents describe the minimal standards that must be met for humane care and treatment of research animals to assure that animals do not suffer unnecessary discomfort, pain, or nigury, and that animals receive proper care and husbandry. Research animals must be cared for and used in a manner that complies with the above documents to protect current and future sponsored support.

ANIMAL USER CERTIFICATION

All personnel listed on this protocol are responsible for reading the above statement and will be held responsible for adhering to all regulations therein, and agree to make written notification in the form of a protocol amendment to the Institutional Animal Care and Use Committee (IACUC) of any proposed changes in the animal experimentation protocol for review and approval prior to proceeding with any animal experimentation.



Protocol # ARS-2019-827 December 18, 2019

For Official Use Only

**Protocol Title:** 

Examination of deer with prion protein amino acid polymorphisms for potential resistance to exposure to the chronic wasting disease (CWD) agent.

animal experimentation.

All personnel working with animals on this protocol:

- must enroll in the NCAH Occupational Health Program to work with animals;
- will be held responsible for pursuing appropriate training; and
- must adhere to the terms and condition of this protocol as approved by the IACUC.
- X The Principal Investigator has read and agrees to abide by the above obligations.

\_\_\_\_\_